The largest database of trusted experimental protocols
Sourced in United States

LNCaP cells are a well-characterized human prostate cancer cell line. They were originally derived from a lymph node metastasis of a human prostate adenocarcinoma. LNCaP cells express prostate-specific antigen (PSA) and are androgen-responsive.

Automatically generated - may contain errors

130 protocols using lncap cell

1

Culturing Prostate Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human prostate cancer cell line C4-2B cells were purchased from MD Anderson Characterized Cell Line Core Facility (Houston, TX), and LNCaP cells were purchased from ATCC (Manassas, VA). Both cells lines were maintained in standard cell culture conditions (5% CO2, 37 °C) and cultured in RPMI-1640 medium, 10% fetal bovine serum, and 1% antibiotic–antimycotic (Gibco).
+ Open protocol
+ Expand
2

Prostate Cancer Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP cells were purchased from ATCC and cultured in RPMI1640 supplemented with 10% FBS (Hyclone, Logan, UT or Invitrogen, Carlsbad, CA, USA). LNCaP-TGF-β1(a) cells overexpressing an HA-tagged constitutively activated TGF-β1 ligand, HA-TGF-β1(a), and control LNCaP (LNCaP-Ctrl) cells were generated as previously described [37 (link)]. Human prostate stromal cell lines HPS19I, HTS33B, and HPS33Q were prepared following a previously described protocol and cultured in Bfs medium: DMEM supplemented with 5% FBS (Hyclone or Invitrogen), 5% Nu serum (Collaborative Research, Bedford, MA), 0.5 μg/mL testosterone, 5 μg/mL insulin, 100 units/mL penicillin, and 100 μg/mL streptomycin (Sigma, St. Louis, MO, USA) [5 (link), 38 (link)].
+ Open protocol
+ Expand
3

Validation of Prostate Cancer Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP cells (ATCC) were a gift from Dr. David Jarrard and were cultured in RPMI medium (Corning) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (HyClone). LNCaP cells were harvested when confluent and frozen in aliquots in growth medium plus 10% DMSO (Fisher Scientific) at -80 ºC and quickly thawed for use in assay validation experiments. White blood cells (WBCs) for assay validation experiments were derived from healthy donor blood or from the blood of a patient with prostate cancer. WBCs were selected on CD45 positivity using magnetic LS MACS columns (Miltenyi). WBCs were frozen in aliquots in PBS plus 10% DMSO (Fisher Scientific) at -80 ºC and quickly thawed for use in assay validation experiments.
+ Open protocol
+ Expand
4

Cell Line Maintenance for Prostate Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
C4-2 cells were purchased from UroCorporation. PC-3 and LNCaP cells were purchased from ATCC. LNCaP-Rf, a castration-resistant subline of LNCaP was described previously [21 (link)]. LNCaP-Rf and C4-2 cells were cultured in RPMI 1640 medium supplemented with 10% charcoal-stripped fetal bovine serum (FBS) (Life Technologies) (or called androgen-depleted medium) and 100 μg/ml penicillin-streptomycin-glutamine (Life Technologies) at 37°C with 5% CO2. PC-3 and LNCaP cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) (Life Technologies).
+ Open protocol
+ Expand
5

Endothelial and Prostate Cancer Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
HUVEC cells (Lonza, Walkersville, MD, USA) were cultured in endothelial growth medium (EGM)-plus media (Lonza, Walkersville, MD, USA) and used before passage 12. To split, the cells were detached using TryplE Express (ThermoFisher Scientific, Waltham, MA, USA), spun at 300 rpm, and resuspended in EGM-plus media. LNCaP cells were purchased from ATCC (Manassas, VA, USA) and maintained in phenol red-free RPMI 1640 medium purchased from Gibco (Gaithersburg, MD, USA) supplemented with 10% FBS and 1% Pen Strep (100 U/mL penicillin + 100 μg/mL streptomycin). Cells were cultured in 5% CO2 and 95% air at 37 °C. For hypoxia experiments, cells were placed in a hypoxia chamber (BioSpherix, Parish, NY, USA) set at 1% O2.
+ Open protocol
+ Expand
6

Doxorubicin and G418 Cytotoxicity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Doxorubicin hydrochloride (Catalog No. D1515) and G418 disulfate salt (Catalog No. A1720) were obtained from Sigma. Hek293 and LNCaP cells were recently purchased form ATCC. HSG (normal human salivary gland cells) were a kind gift of Dr. Gulshan Sunavala Dossabhoy. Dulbecco’s modified Eagle’s medium (DMEM) for HEK293 cells and RPMI for LNCaP cells were purchased from Sigma Aldrich and Caisson labs. Antibodies used in this study were VDAC1 total (Catalog No. ab14734) Abcam, phospho-VDAC1 (a generous gift from Dr. Yumai Chen, UCI), Cyclin A (Catalog No. sc-271645), Cyclin B (Catalog No. sc-245), Cytochrome C (Catalog No. ab65311) Abcam, Complex COX IV (Catalog No. sc-376731), actin (Catalog No. sc-8432), GAPDH (Catalog No. 2118S) CST, Cleaved Caspase-3Asp (175) (Catalog No. 9661) CST, Alpha rabbit IgG-HRP (Catalog No. 7074S) CST. Alpha -mouse IgG-HRP (Catalog No.7076) CST.
+ Open protocol
+ Expand
7

Culturing HeLa and LNCaP cell lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human adenocarcinoma HeLa cell line was purchased from the American Type Culture Collection (Rockville, MD). Cells were maintained in Eagle’s minimum essential medium (Merck-Darmstadt, Germany, EU) with 10% of fetal bovine serum (Gibco—Thermo Fisher Scientific, USA) and 1% penicillin/streptomycin (p/s) at 37 °C with 5% CO2 humidified incubator. Human prostatic cancer LNCaP cells were also from ATCC. Cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 Medium (Gibco—Thermo Fisher Scientific, USA), supplemented with 10% fetal bovine serum (Gibco—Thermo Fisher Scientific, USA) and 1% penicillin/streptomycin (p/s) in 95% humidified air, with 5% CO2 at 37 °C. Cells were passaged once a week after trypsinization and replaced with new medium twice weekly.
+ Open protocol
+ Expand
8

Cell Lines and Antiandrogens Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines were obtained from the following: LNCaP cells from Dr. Leland Chung (Cedars-Sinai Medical Center, Los Angeles, CA, USA) in September 1993, LNCaP95 from Stephen R. Plymate (University of Washington, Seattle, WA, USA), PC3, VCaP and HEK293 were from ATCC (Manassas, VA, USA), DU145 from Victor Ling (British Columbia Cancer Agency, Integrative Oncology) in October 1998. Each cell line was maintained in RPMI-1640 (for LNCaP, LNCaP95, C4-2B), MEM (for HEK293), or DMEM (PC3, VCaP and DU145) medium supplemented with 5% or 10% FBS or charcoal-stripped serum (CSS). Enzalutamide was purchased from Omega Chem (Saint-Romuald, QC, Canada). Bicalutamide from a gift from Dr. Marc Zarenda (AstraZeneca, Cambridge, England). Ralaniten and EPI-7170 were synthesized by us.
+ Open protocol
+ Expand
9

Cell Culture and Genetic Manipulation Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP cells were obtained from ATCC. C4-2 cells and C4-2b were obtained from MD Anderson Cancer Center, Houston, TX. LNCaP-Bic cells were a kind gift from Dr Zoran Culig (General Hospital Feldkirch). DuCaP cells were a kind gift from Philips Research (Eindhoven, The Netherlands). SKOv3 cells were a kind gift from Dr. James Brenton (University of Cambridge). LNCaP, C4-2, C4-2b and DuCaP cells were maintained at 37°C in RPMI 1640 (Invitrogen) containing L-Glutamine and supplemented with 10 % fetal bovine serum (Fbs) (Gibco) in a humidified atmosphere supplied with 5 % CO2. LNCaP-Bic cells were cultured under the same conditions but medium was supplemented with 1 μM Bicalutamide (Enzo Life Science). Cells were routinely sub-cultured 1:4 using 0.25 % Trypsin-EDTA (Invitrogen) when 80-90 % confluency was reached.
Forskolin was obtained from Sigma-Aldrich. A SIK2 inhibitor, ARN3236, was obtained from Arrien Pharmaceuticals with reported low nanomolar IC50 for SIK2 both in activity assays and cell-line experiments. [22 ] SIK2 siRNA sequences were obtained from Dharmacon. [19 (link)] The non-targeting siRNA was obtained from Dharmacon. The pCMV6-Entry-myc/flag construct was obtained from Origene. The pCMV6-Entry-WT-SIK2 -myc/flag and pCMV6-Entry-SIK2-EOS-KI-myc/flag were generated as previously described. [19 (link)]
+ Open protocol
+ Expand
10

Mycoplasma-free LNCaP Cell Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP cells (ATCC) were confirmed to be mycoplasma free everyon month and authenticated using STR profiling. Cells were treated with 5,8,11,14-Eicosatetraynoic acid (ETYA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!